CompletedNCT00649844
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
Medication studyAges 18+Italy
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Città di Castello and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 147
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- Over 18 Years
- Official registry ID
- NCT00649844
- Official title
Show the full official title
Double Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy
Get this study by email
Recruitment & locations
CompletedCittà di Castello · Bassano del Grappa · Bari
17 more locations
- Brescia
- Cagliari
- Catania
- Florence
- Guardiagrele (CH)
- Messina
- Montichiari (brescia)
- Naples
- Parma
- Reggio Calabria
- Roma
- Sassari
- Siena
- Torino
- Trieste
- Verona
- Pfizer Investigational Site
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Clozapine and Ziprasidone.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...